-
Results for the Third Quarter 2019
Sales ended at MNOK 85.5 for the quarter (MNOK 77.6), a 10.2 % growth. Sales as of September increased by 17.6 % and ended at MOK 268.1(MNOK 228.0). Read the full report and presentation below.…
Read more -
Medistim has received clearance for sale of MiraQ™ in Japan
Medistim announces that they have received confirmation from its distributor in Japan that its newest product MiraQ™ is now approved for sale. MiraQ is Medistim's newest generation of products for quality assurance within vascular and…
Read more -
Results for the Second Quarter and First Half 2019
Q2 2019 is the third consecutive quarter with strong growth in both sales revenues and EBIT; 23.1 % and 70.4 % respectively. Read the full report and presentation below. Medistim Q2 19 presentation 2.quarter 2019
Read more -
Results for the First Quarter 2019
Sales in the first quarter amounted to MNOK 88.7 (MNOK 74.1), a 19.7 % growth. Of the MNOK 14.6 in sales growth, MNOK 11.6 was from the US, where the sales increase in NOK was…
Read more -
Annual Report 2018
During 2018, we reached an important milestone when the final results from the 1000 patients prospective, multi-center registry study REQUEST was presented. In this study, some of the best cardiac centers in Europe, Canada, and…
Read more -
Results for Fourth Quarter and Preliminary Results for Medistim for 2018
Currency neutral sales of own products increased with 25.5 % for the quarter. For 2018, currency neutral growth in sales of own products was 10.0%. EBIT for the quarter ended at MNOK 27.8 (MNOK 16.4),…
Read more -
Results for the Third Quarter 2018
Sales as of September increased by 4.0 % and ended at MOK 228.0 (MNOK 219.2). Revenue from own products showed a currency neutral decline of 0.4 % for the quarter and a currency neutral growth…
Read more -
REQUEST Final Results: Strengthening the Recommendation for Medistim’s Dual Technology
The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and Transit Time Flow Measurement (TTFM) performed with Medistim's VeriQ C or MiraQ devices will change the…
Read more -
Results for the Second Quarter 2018
Sales for the first half of 2018 increased by 4,7 % and ended at MNOK 150,4 (MNOK 143,5). Currency neutral growth of own products was 19,3 % for the second quarter. Operating profit (EBIT) ended…
Read more -
REQUEST Interim Results: Significant Impact on Surgical Strategy with Medistim’s Devices
The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and transit time flow measurement (TTFM) performed with Medistim’s VeriQ C or MiraQ devices will change the…
Read more
PC: Hold CTRL and press + (plus) to enlarge or - (minus) to shrink.
MAC: Hold CMD and press + (plus) to enlarge or - (minus) to shrink.